Article
FDA Approves First Generic Version of Viagra
Author(s):
Erectile dysfunction drug expected to become available on December 11, 2017.
The FDA has approved Teva’s generic version of sildenafil citrate (Viagra).
The erectile dysfunction drug is expected to become available to the public on December 11, 2017.
The treatment will be available in 25, 50, and 100 mg tablets, and Teva has the exclusive rights to the generic for 180 days.
Pfizer, which markets the brand-name version, will not lose patent protection until 2020. However, it reached in agreement with Teva in 2013 that allows the company to market a generic edition in 2017.
The most common adverse reactions associated with this treatment are headache, flushing, abnormal vision, nasal congestion, and nausea.
Healthcare professionals are advised to consider their patients’ use of nitrates, alpha-blockers, amlodopine, ritonavir, and other CYP3A4 inhibitors prior to prescribing the medication.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
